SCHEMBL23705293

SCHEMBL23705293

COC(=O)C1CCOc2ccc(Br)cc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.42
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PTGDR2 Q9Y5Y4 4/20 0.40
HCRTR2 O43614 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAOB P27338 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
BLM P54132 1/20 0.37
PIK3CG P48736 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15897694 0.89 KDM4C (0.43) ADRA2ASLC6A4SLC6A3PTGDR2SMN1; SMN2
SCHEMBL15271104 0.86 HCRTR2 (0.44) SLC6A4SLC6A3HCRTR2SMN1; SMN2MAPT
SCHEMBL30041950 0.86 HCRTR2 (0.44) SLC6A4SLC6A3HCRTR2SMN1; SMN2MAPT
SCHEMBL27817330 0.84 ADRA2A (0.47) ADRA2APTGDR2HCRTR2MAOBNPC1
SCHEMBL9431997 0.83 TRPV1 (0.41) SLC6A4SLC6A3PTGDR2HCRTR2MAOB
SCHEMBL26488602 0.83 MAP3K14 (0.46) ADRA2APTGDR2HCRTR2NPC1MAPT
SCHEMBL5846862 0.83 SLC6A4 (0.39) SLC6A4SLC6A3
SCHEMBL5846869 0.83 SLC6A4 (0.39) SLC6A4SLC6A3
SCHEMBL5846860 0.83 SLC6A4 (0.39) SLC6A4SLC6A3
SCHEMBL14059245 0.83 CYP19A1 (0.43) SLC6A4SLC6A3SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ADRA2A 4143/4885SLC6A4 3358/4885SLC6A3 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.